rosiglitazone has been researched along with 3-chloro-4-(3-(7-propyl-3-trifluoromethyl-6-benzisoxazolyl)propylthio)phenylacetic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, GD; Berger, J; Doebber, T; Han, W; MacNaul, K; Moller, DE; Mosley, R; Sahoo, SP; Santini, C; Tolman, RL; Wu, M | 1 |
| Ahmad Noruddin, NA; Al-Najjar, BO; Shu-Chien, AC; Taha, MO; Tengku Muhammad, TS; Wahab, HA | 1 |
2 other study(ies) available for rosiglitazone and 3-chloro-4-(3-(7-propyl-3-trifluoromethyl-6-benzisoxazolyl)propylthio)phenylacetic acid
| Article | Year |
|---|---|
Phenylacetic acid derivatives as hPPAR agonists.
Topics: Animals; Blood Glucose; Dose-Response Relationship, Drug; Drug Design; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Phenylacetates; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2003 |
Discovery of new nanomolar peroxisome proliferator-activated receptor γ activators via elaborate ligand-based modeling.
Topics: Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Discovery; Hep G2 Cells; Humans; Ligands; Models, Molecular; Molecular Structure; PPAR gamma; Quantitative Structure-Activity Relationship; ROC Curve; Stereoisomerism | 2011 |